ContraVir’s mandate is to create beneficial drug therapies to address liver disease including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). We are open to unique partnering opportunities within this field. To initiate discussions, please contact us or complete the form below.
ContraVir Partnership Inquiry
A member of our team will follow-up with you shortly.